non-small cell lung cancer
The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced non-small cell lung cancer with EGFR mutations has changed the strategy of treatment of theses patients.
The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced <span class="disease" id="21777763-1-88-114">non-small cell lung cancer</span> with <span class="gene" id="21777763-1-120-124">EGFR</span> mutations has changed the strategy of treatment of theses patients.